Biosimulation Market by Offering (Services, Software), Delivery Model (Ownership Models, Subscription Models), End-User, Application - Global Forecast 2024-2030
Description
Biosimulation Market by Offering (Services, Software), Delivery Model (Ownership Models, Subscription Models), End-User, Application - Global Forecast 2024-2030
The Biosimulation Market size was estimated at USD 3.81 billion in 2023 and expected to reach USD 4.40 billion in 2024, at a CAGR 14.55% to reach USD 9.87 billion by 2030.
Biosimulation combines mathematics, biology, and computer programming to create simulations to test hypotheses, predict outcomes, and explore new possibilities in biotechnology. By simulating biological phenomena such as gene expression, metabolism, and cell growth, biosimulation helps researchers better understand the complexities of life and develop new products for healthcare. The increasing development of new drugs and medicines and the growing government focus on integrating digitalized technologies in pharmaceutical and biopharmaceutical sectors are elevating the need for biosimulation systems. However, the high cost associated with developing biosimulation software hampers market growth. The growing integration of computer-aided design (CAD) and virtual reality (VR) technologies, as well as advancements in artificial intelligence (AI) and machine learning (ML) for the development of new biosimulation software, is expected to expand the scope of the biosimulation market.
Regional Insights
The Americas region showcases a highly developing landscape for the biosimulation market owing to the presence of major established players in the United States and their ongoing efforts to advance biosimulation software. Well-established regulatory authorities such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), and Health Canada to ensure the safety and efficiency of drug development and clinical trials are benefiting the market growth across the Americas, Europe, and Asia-Pacific. Considering the EMEA region, the increasing investment in drug development and clinical trials across UK, Germany, and France is expanding the adoption of biosimulation software & services. The increasing number of chronic diseases across Asia-Pacific encourages government and regulatory authorities to expand their funding activities for drug development which is expected to create a platform for developing the biosimulation market. The presence of various initiatives such as Australia's Drug Discovery Initiative and Medical Research Commercialisation Initiative that aims at pharmaceutical research and development (R&D) activities is expanding the usage of biosimulation in Asia-pacific.
Market Insights
- Market Dynamics
The market dynamics represent an ever-changing landscape of the Biosimulation Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.- Market Drivers
- Growing emphasis on research of personalized medicine
- Supportive regulatory approvals for use of biosimulation to enhance the development of safe medicines
- Market Restraints
- Upscaled prices involved in installations and technique developments for biosimulation
- Market Opportunities
- Ongoing advancements in simulation solutions to enhance the novel biologic therapies
- Rising investments for drug developments and drug testings
- Market Challenges
- Lack of awareness coupled with complexities for creating accurate outcomes
- Market Segmentation Analysis
- Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization
- Delivery Model: Growing preference for ownership model in biosimulation for providing full control to users
- End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies
- Application: Increasing application of biosimulation for drug development
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biosimulation Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biosimulation Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments- Certara and DNDi Partnering to Fast-track Data Submissions and Accelerate Drug Approvals for Neglected Patients
Certara Inc. has partnered with the Drugs for Neglected Diseases Initiative (DNDi) to utilize Certara's data science platform, Pinnacle 21 Enterprise (P21E). This collaboration aims to enhance data flow and expedite the analysis and submission of new treatments for health authority review.
Certara Launches Version 8.4 of Phoenix Biosimulation Software for Drug Development
Certara Inc. launched Version 8.4 of its Phoenix biosimulation software for drug development. This new version features improved usability and scalability in heterogeneous computing environments and enable users to create more efficient workflows by utilizing the power of high-performance computing.
Certara Amplifies CODEX Platform Capabilities with AI for Drug Discovery
Certara Inc. expanded the horizons of AI in drug discovery by introducing artificial intelligence (AI) capabilities and data fabric connectivity to its clinical trials outcome analytics platform, CODEX. The Codex platform has been enhanced with additional capabilities, allowing users to accurately simulate their experiments and quickly generate unprecedented datasets for further analysis.
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biosimulation Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Biosimulation Market, highlighting leading vendors and their innovative profiles. These include Advanced Chemistry Development, Inc., Aitia, Allucent, Applied BioMath, LLC, Biomed Simulation, Inc., BioSimulation Consulting Inc., Cadence Design Systems, Inc., Cell Works Group, Inc., Certara, Inc., Chemical Computing Group ULC, Compugen Ltd., Crystal Pharmatech Co., Ltd., Dassault Systèmes SE, Genedata AG, Immunetrics Inc, In Silico Biosciences, Inc., INOSIM Software GmbH, Instem PLC, Laboratory Corporation of America Holdings, Model Vitals, Physiomics PLC, Quotient Sciences Limited, Resolution Medical, Rosa & Co LLC, Schrodinger, Inc., Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life., VIRTUALMAN, and Yokogawa Electric Corporation.
Market Segmentation & Coverage
This research report categorizes the Biosimulation Market to forecast the revenues and analyze trends in each of the following sub-markets:- Offering
- Services
- Contract Services
- In-House Services
- Software
- Molecular Modeling & Simulation Software
- PBPK Modeling & Simulation Software
- PK/PD Modeling & Simulation Software
- Toxicity Prediction Software
- Trial Design Software
- Delivery Model
- Ownership Models
- Subscription Models
- End-User
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies
- Regulatory Authorities
- Research Institutes
- Application
- Drug Development
- Clinical Trials
- Preclinical Testing
- ADME/Tox
- PK/PD
- Drug Discovery
- Lead Identification & Optimization
- Target Identification & Validation
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
- Americas
- Drug Development
- Services
- Market Drivers
Table of Contents
185 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing emphasis on research of personalized medicine
- 5.1.1.2. Supportive regulatory approvals for use of biosimulation to enhance the development of safe medicines
- 5.1.2. Restraints
- 5.1.2.1. Upscaled prices involved in installations and technique developments for biosimulation
- 5.1.3. Opportunities
- 5.1.3.1. Ongoing advancements in simulation solutions to enhance the novel biologic therapies
- 5.1.3.2. Rising investments for drug developments and drug testings
- 5.1.4. Challenges
- 5.1.4.1. Lack of awareness coupled with complexities for creating accurate outcomes
- 5.2. Market Segmentation Analysis
- 5.2.1. Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization
- 5.2.2. Delivery Model: Growing preference for ownership model in biosimulation for providing full control to users
- 5.2.3. End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies
- 5.2.4. Application: Increasing application of biosimulation for drug development
- 5.3. Market Trend Analysis
- 5.3.1. Significant investments in drug development and collaborative activities to expand the usage of biosimulation in the Americas
- 5.3.2. Government initiatives to encourage the adoption of innovative technologies in pharmaceutical research in the APAC
- 5.3.3. Increasing clinical trials and drug development activities expanding the scope of biosimulation in the EMEA region
- 5.4. Cumulative Impact of Russia-Ukraine Conflict
- 5.5. Cumulative Impact of High Inflation
- 5.6. Porter’s Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
- 5.7. Value Chain & Critical Path Analysis
- 5.8. Regulatory Framework Analysis
- 6. Biosimulation Market, by Offering
- 6.1. Introduction
- 6.2. Services
- 6.3. Software
- 7. Biosimulation Market, by Delivery Model
- 7.1. Introduction
- 7.2. Ownership Models
- 7.3. Subscription Models
- 8. Biosimulation Market, by End-User
- 8.1. Introduction
- 8.2. Contract Research Organizations
- 8.3. Pharmaceutical & Biotechnology Companies
- 8.4. Regulatory Authorities
- 8.5. Research Institutes
- 9. Biosimulation Market, by Application
- 9.1. Introduction
- 9.2. Drug Development
- 9.3. Drug Discovery
- 10. Americas Biosimulation Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Biosimulation Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Biosimulation Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. Market Share Analysis, 2023
- 13.2. FPNV Positioning Matrix, 2023
- 13.3. Competitive Scenario Analysis
- 13.3.1. Certara and DNDi Partnering to Fast-track Data Submissions and Accelerate Drug Approvals for Neglected Patients
- 13.3.2. Certara Launches Version 8.4 of Phoenix Biosimulation Software for Drug Development
- 13.3.3. Certara Amplifies CODEX Platform Capabilities with AI for Drug Discovery
- 13.3.4. Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
- 13.3.5. Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
- 13.3.6. Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
- 13.3.7. Simulations Plus Releases Redesigned NAFLDsym QSP Software Tool
- 13.3.8. Cellworks Expands into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets
- 13.3.9. Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation
- 13.3.10. Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma
- 13.3.11. Applied BioMath, LLC Announces a Continuation of their Collaboration with Celsius Therapeutics for Systems Pharmacology Modeling in Inflammatory Bowel Disease
- 13.3.12. GNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development
- 13.3.13. Cadence Expands into Molecular Simulation with Acquisition of OpenEye Scientific, a Pioneering Leader in Computational Molecular Design
- 13.3.14. Resolution Medical Acquires LifeTec Group
- 13.3.15. Colorcon Ventures Invests in AI-Driven Bio-simulation Company VeriSIM Life
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.2. Key Product Portfolio
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
